Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 3/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.50 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.50 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.50 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910280 | 0.92 | L3MBTL1 (0.73) | L3MBTL1TAAR1ALDH1A1KDM4EMAPT | |
| SCHEMBL10055000 | 0.91 | L3MBTL1 (0.86) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| SCHEMBL24375975 | 0.87 | L3MBTL1 (0.95) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| SCHEMBL21186859 | 0.87 | L3MBTL1 (0.95) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| SCHEMBL88597 | 0.87 | L3MBTL1 (0.95) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| Hydrochloric Acid SCHEMBL8746161 | 0.85 | L3MBTL1 (1.00) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| SCHEMBL30266145 | 0.83 | L3MBTL1 (0.73) | L3MBTL1ALDH1A1MAPTKCNH2KCNH3 | |
| SCHEMBL11653014 | 0.82 | L3MBTL1 (0.86) | L3MBTL1TAAR1ALDH1A1MAPTNPC1 | |
| SCHEMBL248884 | 0.82 | L3MBTL1 (0.70) | L3MBTL1TAAR1ALDH1A1MAPTPLAAT3 | |
| SCHEMBL2309185 | 0.82 | L3MBTL1 (0.70) | L3MBTL1TAAR1ALDH1A1MAPTPLAAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110550992-B | Green synthesis method of amino alcohol compound under catalysis of visible light | 杭州师范大学 | 2022-06-21 | — | — | CN | disclosed |
| US-8039474-B2 | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| EP-1833791-B1 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-08-03 | — | — | EP | disclosed |
| CN-101084190-B | 2,3,4, 9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2018364-A1 | THERAPEUTIC FLUOROETHYL UREAS | Allergan, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| CN-101084190-A | 2,3,4, 9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-05 | — | — | CN | disclosed |
| WO-2007137029-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1833791-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006070325-A2 | 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-07-06 | — | — | WO | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-0573548-A1 | NEUROPROTECTANT AGENTS. | AMERICAN HOME PROD (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992014813-A1 | NEUROPROTECTANT AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270414-A1 | 2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, CRHR2, GRK2 | L3MBTL1 4883/4885TAAR1 348/4885ALDH1A1 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.